WALTHAM, Mass., Aug. 29, 2011 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel, biomarker-based diagnostics, announced today that results from a sub-study of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) trial were presented at the European Society of Cardiology (ESC) Congress 2011, in Paris, France. The results from the sub-study demonstrated that patients with plasma levels of galectin-3 below the median derived a marked clinical benefit from rosuvastatin (statin) treatment, while no benefit from rosuvastatin (statin) treatment was observed among patients with higher levels of galectin-3.
